Return to homepagePandemic Pact

to evaluate the effectiveness of COVID-19 vaccines against variants of SARS-CoV-2 in a national immunization program in Bangladesh

Grant number: INV-034303

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021

  • Known Financial Commitments (USD)

    $1,280,471

  • Funder

    Gates Foundation

  • Research Location

    Bangladesh

  • Lead Research Institution

    International Centre for Diarrhoeal Disease Research, Bangladesh

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A

5 Publications linked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh.

Evaluating the effectiveness of COVID-19 vaccines during a period of Omicron variant predominance among Bangladeshi population: A test-negative design measurement.

Spike specific IgG3 and nucleocapsid IgG response in serum serve as distinguishing immunological markers between SARS-CoV-2 infection and vaccination.

Measuring the Effectiveness of COVID-19 Vaccines Used during a Surge of the Delta Variant of SARS-CoV-2 in Bangladesh: A Test-Negative Design Evaluation.

Covishield vaccine induces robust immune responses in Bangladeshi adults.